Zivo Bioscience, Inc.

Overview

Compare with Kalaris Therapeutics, Inc., Instil Bio, Inc. or Abpro Holdings, Inc., or pick any stock.

• TickerZIVO on OTC¹
• IndustryBiological Products, (No Diagnostic Substances)¹
• HeadquartersBloomfield Hills, Michigan¹
• Incorporated inNV²
• Business address21 E. Long Lake Road, Suite 100, Bloomfield Hills, Mi 48304²
• Filer categoryNon-accelerated filer, Smaller reporting company²
• Legal formCorporation

See how the biggest companies compare on our leaderboards

Unless we state otherwise or the context otherwise requires, references in this Annual Report on Form 10-K to “we,” “our,” “us,” “ZIVO,” “the Registrant” or “the Company” refer to Zivo Bioscience, Inc., a Nevada corporation, and its subsidiaries.³ From its latest annual report

Corporate structure

Zivo Bioscience, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Zivo Bioscience, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Properties, in its own words

The Company’s principal executive office is located at 2125 Butterfield Road, Suite 100, Troy, MI 48084 in a facility where we lease roughly 3,200 square feet. We believe that our existing facilities are adequate for our current needs. If we determine that additional or new facilities are needed in the future, we believe that sufficient options would be available to us on commercially reasonable terms. We also lease a laboratory and office (roughly 2,700 square feet) at 608 Danley Drive, Unit #1, Fort Myers, FL 33907.

Item 2 of the 10-K filed Mar 18, 2025.³

Leadership

Who has led Zivo Bioscience, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerAndrew A. Dahl Dec 20, 2011 to Oct 25, 2021¹³
• Chief executive officerPeter Vitulli Sep 22, 2009 to Sep 22, 2009¹⁴
• Chief executive officerHoward R. Baer Jan 20, 2006 to Jan 25, 2006¹⁵
• Chief executive officerThomas Ingolia Dec 11, 2006 to Dec 11, 2006¹⁶
• ChairStephen J. Warner Jan 5, 2012 to Jan 5, 2012¹⁷
• ChairHoward R. Baer Jan 20, 2006 to Jan 25, 2006¹⁵
• PresidentAndrew A. Dahl Dec 20, 2011 to Oct 25, 2021¹³
• Chief financial officerWilliam A. Sullivan Dec 29, 2025 to now¹⁸
• Chief financial officerKeith Marchiando Jan 5, 2021 to Jun 6, 2024¹⁹
• Chief financial officerChristopher D. Maggiore Jan 10, 2013 to Jan 10, 2013²⁰
• Chief financial officerPhilip M. Rice Ii. Nov 15, 2011 to Dec 1, 2020²¹
• Chief financial officerJanet Crance Jun 29, 2010 to Jun 29, 2010²²

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive OfficerJohn B. Payne named Jul 17, 2023³³
• DirectorAllison A. Cornell named Jul 17, 2023³³

Former names

• HEALTH ENHANCEMENT PRODUCTS INCFeb 6, 2004 to Oct 16, 2014²
• WESTERN GLORY HOLE INCJun 19, 2000 to Jan 26, 2004²

Timeline

1. Mar 30, 20268-K Executive or director change; Regulation FD disclosure³⁴
2. Dec 23, 20258-K Executive or director change³⁵
3. Sep 10, 20258-K Regulation FD disclosure³⁶
4. Aug 18, 20258-K Executive or director change³⁷
5. Jul 14, 20258-K Entered a material agreement; New debt or obligation³⁸
6. Jun 11, 20258-K Shareholder vote³⁹
7. Jan 27, 20258-K Unregistered sale of shares⁴⁰
8. Jan 15, 20258-K Entered a material agreement⁴¹
9. Jan 7, 20258-K Other events⁴²
10. Nov 15, 20248-K Entered a material agreement; New debt or obligation⁴³
11. Oct 18, 20248-K Unregistered sale of shares⁴⁴
12. Jul 17, 20248-K Executive or director change⁴⁵
13. Dec 20, 2011New chief executive Andrew A. Dahl becomes CEO¹³
14. Sep 22, 2009New chief executive Peter Vitulli becomes CEO¹⁴
15. Dec 11, 2006New chief executive Thomas Ingolia becomes CEO¹⁶
16. Jan 20, 2006New chief executive Howard R. Baer becomes CEO¹⁵

Filings

185 filings to the SEC since October 2021: 5 annual reports, 14 quarterly reports, 45 major events, 78 insider forms, 11 large holders, 1 private raises, 31 other. The latest 20:

1. Apr 24, 20264 EDGAR
2. Apr 1, 2026EFFECT EDGAR
3. Mar 31, 202615-12G EDGAR
4. Mar 31, 2026S-8 POS S-8 EDGAR
5. Mar 31, 2026POS AM EDGAR
6. Mar 30, 20268-K EDGAR
7. Mar 3, 20264 PRIMARY DOCUMENT EDGAR
8. Feb 27, 2026SCHEDULE 13D/A EDGAR
9. Feb 17, 20264 EDGAR
10. Feb 12, 20264 PRIMARY DOCUMENT EDGAR
11. Jan 28, 20264 PRIMARY DOCUMENT EDGAR
12. Jan 28, 20264 PRIMARY DOCUMENT EDGAR
13. Jan 27, 20264 PRIMARY DOCUMENT EDGAR
14. Jan 27, 20264 PRIMARY DOCUMENT EDGAR
15. Dec 29, 20253 EDGAR
16. Dec 23, 20258-K EDGAR
17. Dec 2, 20254 PRIMARY DOCUMENT EDGAR
18. Nov 14, 202510-Q EDGAR
19. Oct 20, 20254 EDGAR
20. Oct 14, 20254 PRIMARY DOCUMENT EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

38 open-market trades by officers, directors and large owners since October 2021: 37 buys and 1 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Mark E. StromeSCHEDULE 13D/A, 1 filing Feb 27, 2026⁴⁶
• HEP INVESTMENTS LLCSC 13D/A, 2 filings Mar 14, 2024 to Oct 1, 2024⁴⁷
• Alison A. CornellSC 13D, 1 filing Jun 12, 2024⁴⁸
• John Bernard PayneSC 13D, 1 filing Jun 12, 2024⁴⁹
• Keith MarchiandoSC 13D, 1 filing Jun 12, 2024⁵⁰
• Christopher D. MaggioreSC 13D/A, 3 filings Feb 14, 2023 to Jun 7, 2024⁵¹
• STROME MEZZANINE FUND, LPSC 13D/A, 2 filings Oct 30, 2023 to Apr 9, 2024⁵²

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Money raised

Private offerings the company reported to the SEC on Form D.

1. Jun 30, 2023Raised $4 million in a private offering of securities Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Zivo Bioscience, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARZivo Bioscience, Inc.¹
• CIK0001101026
• Employer ID (EIN)87-0699977³
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company³
• Incorporated inNevada³
• Fiscal year endsDecember 31¹
• Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address21 E. Long Lake Road, Suite 100, Bloomfield Hills, MI 48304¹
• Phone(248) 452 9866¹
• Shares outstanding3,888,595 as of Nov 9, 2025¹²
• Public float$15.6M as of Jun 28, 2024³
• AuditorBDO USA, P.C., Troy, Michigan PCAOB ID 243; no auditor attestation of internal control over financial reporting³
• On EDGAR sinceApr 20, 2000¹
• Filings757 in all: 4 (196), 8-K (151), 10-Q (54), D/A (31), 3 (30), SC 13D/A (27), 10QSB (23), D (20)¹
  All 57 form types

  DEF 14A (18), 10-K (17), SC 13D (14), CORRESP (11), NT 10-Q (11), SC 13G/A (11), UPLOAD (11), NT 10-K (10), 4/A (9), REGDEX/A (9), 10KSB (8), PRE 14A (8), 10-Q/A (7), 8-K/A (6), DEFR14A (6), SC 13G (6), DEFA14A (5), S-1/A (5), EFFECT (4), REGDEX (4), ARS (3), RW (3), S-1 (3), 10-K/A (2), 10KSB/A (2), 10QSB/A (2), 3/A (2), 5 (2), PREM14C (2), PRER14A (2), S-3 (2), S-8 (2), SCHEDULE 13D/A (2), 10SB12G (1), 10SB12G/A (1), 15-12G (1), 25-NSE (1), 424B3 (1), 424B4 (1), 424B5 (1), 8-A12B (1), CERT (1), DEF 14C (1), NT 10-K/A (1), NT 10-Q/A (1), POS AM (1), S-1MEF (1), S-8 POS (1), SB-2 (1)

• Latest filingsAnnual report (10-K) Mar 18, 2025
  Quarterly report (10-Q) Nov 14, 2025
  Proxy statement (DEF 14A) Apr 25, 2025
  Latest 8-K (8-K) Mar 30, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 18, 2025 (Section 12(b) of the Exchange Act).³

Risk factors and legal proceedings

The risks Zivo Bioscience, Inc. names in Item 1A of its 10-K filed Mar 18, 2025: 33 risks under these headings, as written.³

• Risks Relating to Our Business
• Worldwide economic and social instability could adversely affect our revenue, financial condition, or results of operations.
• The Company is exposed to risks of political instability and changes in government policies, laws and regulations in Peru.
• We have incurred, and may continue to incur increased costs and demands upon management as a result of being a public company.
• We have a history of operating losses, and we may not be able to achieve or sustain profitability. In addition, we may be unable to continue as a going concern.
• We will require substantial additional financing to achieve our goals, and our failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development efforts.
• Our production of algae involves an agricultural process, subject to such risks as weather, disease, contamination, supply chain interruption, and water availability.
• We rely on third parties to grow our proprietary algae strains and conduct research, and preclinical and clinical testing, and these third parties may not perform satisfactorily.
• Because our ZIVO algae is currently produced by only one grower, the loss of this grower would have a material adverse impact on our operating results and cash flows.
• Because our algae product is marketed and distributed by only one distributor, the loss of this distributor would have an adverse effect on near term revenue generation and cash flows.
• Failure to proportionally advance both our manufacturing capacity and distribution networks could adversely affect our operating results, and near-term and long-term growth plans.
• If we fail to attract and keep our Chief Executive Officer and Chief Financial Officer, senior management and key scientific personnel, we may be unable to successfully develop our therapeutic candidates, conduct our clinical trials and commercialize our therapeutic candidates.

Legal proceedings

The Company may be subject to various claims, complaints, and legal actions that arise from time to time in the normal course of business. There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on the Company’s business, financial position, results of operations, or cash flows.

The opening of Item 3, Legal Proceedings.³